{"paper_id":"3e4b5d24-2e4b-4e17-82fa-0771c0d9c97f","body_text":"Predictive factors of progression in fibrosing interstitial lung disease patients with gender-age-physiology stage 0 or I | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Predictive factors of progression in fibrosing interstitial lung disease patients with gender-age-physiology stage 0 or I Masaki Okamoto, Kiminori Fujimoto, Tomonori Chikasue, Toyoshi Yanagihara, and 9 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4513072/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The prognostic factors in mild fibrosing interstitial lung disease (FILD) have not been established. We retrospectively attempted to identify predictive factors of annual progression in mild FILD with gender-age-physiology (GAP) stage 0 or I using logistic regression analysis, adjusting for confounding factors associated with prognosis. Annual progression was defined as more than 10% decrease in forced vital capacity (FVC) or 15% decrease in diffusing capacity of the lungs for carbon monoxide (D LCO ), developing acute exacerbation, or death due to FILD. Univariate analysis showed that higher age, diagnosis of fibrotic hypersensitivity pneumonia (HP), definite usual interstitial pneumonia (UIP) pattern on CT, GAP stage I, lowest SpO 2 and decrease in SpO 2 , and shorter walk distance in 6-minute walk test (6MWT) were significantly associated with a higher incidence of annual progression. Multivariate analysis showed that independent predictive factors of higher annual progression were diagnosis of idiopathic pulmonary fibrosis and fibrotic HP, definite UIP pattern on CT, GAP stage I, lower D LCO , lowest SpO 2 and decrease in SpO 2 in the 6MWT, and higher chronic pulmonary emphysema assessment test. Evaluating prognostic factors in patients with mild FILD has potential to identify patients who are suitable for early intervention with antifibrotic therapy. Biological sciences/Physiology Biological sciences/Physiology/Respiration fibrosing interstitial lung disease 6-minute walk test progression gender-age-physiology stage prognostic factor Figures Figure 1 Figure 2 Introduction The comprehensive disease term “fibrosing interstitial lung disease” (FILD) includes various subtypes of radiological and histopathological lung parenchymal fibrosis with or without inflammation 1–4 . Among the idiopathic interstitial pneumonias (IIPs), idiopathic pulmonary fibrosis (IPF), pathologically defined as usual interstitial pneumonia (UIP), is the most prevalent and has no known cause 1–4 . IPF carries a poor prognosis, with patients having a median survival of only about 3 years 5 . Non-IPF-FILD patients with progressive characteristics, defined as progressive pulmonary fibrosis by global guidelines and various studies, have similarly grave survival as IPF 1,6 . In recent years two antifibrotic agents, nintedanib and pirfenidone, have demonstrated safety and efficacy in the treatment for IPF 7,8 . Nintedanib, in particular, was shown to slow the decline in forced vital capacity (FVC) and reduced the incidence of acute exacerbation (AE) in IPF patients in two replicate randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) 7 . Furthermore, a meta-analysis of 12,956 patients with IPF from eight randomized controlled trials and 18 cohort studies revealed that treatment with antifibrotic drugs, including nintedanib and pirfenidone, lowered the risk of all-cause mortality and AE 9 . More recently, the INBUILD phase 3 trial reported that nintedanib slowed the decline of FVC over 52 weeks in patients with non-IPF FILD with progressive fibrosis 10 . The interstitial lung disease gender-age-physiology (ILD-GAP) staging system is a promising staging tool for assessing disease severity in accordance with the GAP score, which predicts IPF patient survival based on multiple factors as reported previously, i.e., classifying patients into three stages based on clinical (e.g., gender or age) and physiological (e.g., FVC and diffusing capacity of the lung for carbon monoxide (D LCO )) variables 11 . The GAP stage is regarded as a well-validated system for classifying the severity of FILD, because as a system it is strongly associated with mortality; for example, 3-year predicted mortality is 10.2% in stage 0 (score 0–1), 26.9% in stage I (score 2–3), 49.2% in stage II (score 4–5), and 74.8% in stage III (score ≥6) 11 . The GAP stage was believed to contribute to decision-making regarding treatment for FILD including drug therapy, lung transplantation, and palliative care 11 . For example, patients with GAP stage 0 or I will only occasionally be referred for drug therapy. However, effectiveness of treatment with antifibrotic drugs for early FILD patients has been reported recently 12,13 . In INMARK, a phase 3 trial for mild-IPF patients with more than 80% FVC, nintedanib suppressed the decline in FVC over 12 weeks 12 . In the INBUILD trial, nintedanib suppressed the decrease in FVC over 52 weeks regardless of GAP stage and baseline FVC 10,13 . Similarly, a subgroup analysis of the INPULSIS trials suggested no difference in the effect of nintedanib on FVC decline between patients with GAP stage I and those with GAP stage II/III at baseline 14 . However, early intervention with antifibrotic drugs in a proportion of patients with mild FILD may lead to excessive side effects and economic burden. The effectiveness and safety of early intervention with antifibrotic drugs in FILD patients remain uncertain. To identify patients with mild FILD who may benefit from early intervention, it is crucial to determine predictive factors of the outcome. In the present study, we aimed to analyze prognostic factors in patients with mild FILD with GAP stage 0 or I to better inform treatment decisions and optimize patient outcomes. Patients and methods Patient selection In the present study, we retrospectively analyzed consecutive patients with FILD who underwent a hospitalization examination program for FILD from 2019 to 2022. The inclusion criteria for analysis were as follows: patients diagnosed with FILD according to multidisciplinary discussion (MDD) based on global guidelines of IPF, IIPs, systemic sclerosis (SSc), polymyositis (PM), rheumatoid arthritis (RA), Sjögren’s syndrome (SS), and microscopic polyangiitis (MPA) 1–4,15–19 ; and patients with GAP stage 0 (score 0 or 1) or I (score 2 or 3) as previously reported 11 . Exclusion criteria were as follows: patients who could not regularly visit our hospital at least 1 year after hospitalization for the examination program; and patients who could not undergo a pulmonary function test at least every 6 months. Diagnosis of AE of IPF was defined in accordance with the criteria detailed in a previous report 20 . Study protocol Clinical data at hospitalization for the examination program were collected to determine factors predicting progression of FILD. Annual progression of FILD was defined as more than 10% decrease in FVC or 15% decrease in D LCO , developing AE, or death during hospitalization for the examination program. Patients’ outcome measures including chronic obstructive pulmonary disease assessment test (CAT) 21,22 , the Nagasaki University Respiratory Activities of Daily Living Questionnaire (NRADL) 23 , Short Form 36 (SF-36) 24 , Hospital Anxiety and Depression Scale–Anxiety (HADS-A) and HADS–depression (HADS-D) 25 , limb skeletal muscle mass, knee extension strength, and grip strength were measured for evaluation of respiratory symptoms. Activities of daily living, health-related quality of life, the psychological condition, and muscle strength were evaluated at hospitalization for the examination program. Overall survival (OS) was measured from the day of hospitalization for the examination program to the final observation day (February 24, 2024). Pulmonary function tests Pulmonary function tests, including FVC and forced expiratory volume in 1 second, were performed using an electronic spirometer. The D LCO was measured using the single-breath technique. These tests were performed according to the guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS) 26 . Six-minute walk test The 6-minute walk test (6MWT) was performed according to the ATS statement 27 . Patients were instructed to walk as fast as possible and were allowed to slow down or stop if necessary during examination. saturation of percutaneous oxygen (SpO 2 ), heart rate, modified Borg (mBorg) scale, and 6-minute walk distance (6MWD) were monitored and recorded. CT assessment of emphysema (CT-Goddard score) All CT examinations were performed using a 128-channel MDCT (Aquilion ONE ViSION®, Cannon Medical Systems, Japan). To evaluate pulmonary emphysema in both lungs, CT images with 1.0-mm slice thickness were reconstructed at intervals of 1.0 mm. The CT images of each patient were transferred to a workstation with the Synapse Vincent (Fujifilm Medical, Tokyo, Japan). According to the corresponding Goddard classification 28 , the entire field of each lung was divided into three areas (levels of the aortic arch, the carina, and the upper end of the diaphragm), with a total of six areas for both sides. Areas of low attenuation less than – 950 Hounsfield unit were considered to indicate emphysema 29 . Thereafter, the severity of emphysema was scored using a 5-point scale for each area as follows: emphysema extending to < 5% of the area scored 0 points; ≥ 5% and < 25%, 1 point; ≥ 25% and < 50%, 2 points; ≥ 50% and < 75%, 3 points; and ≥ 75%, 4 points. The total points from all six areas for each patient were calculated as a CT-Goddard score ranging from 0 to 24. Statistical analysis Data are expressed as the median (25th–75th percentiles of the interquartile range). For comparison of clinical data between two groups, we used the Wilcoxon rank-sum test and Fisher’s exact test as appropriate. In the logistic regression analysis using backward elimination, we detected variables associated with annual progression of FILD by univariate analyses and multivariate analysis, adjusting for covariates with prognosis including age, gender, FVC, D LCO , diagnosis of IPF, and immunosuppressive therapy including corticosteroids or immunosuppressants for more than 180 days, and covariates with desaturation as Goddard score based on previous reports 1–4,11,30 . P <0.10 in univariate analysis was set as the criterion for multivariate analysis. The cut-off levels of lowest SpO 2 and decrease in SpO 2 , D LCO , and CAT by receiver-operating characteristic (ROC) curve analysis were set as 90%, 4%, 40%, and 10, respectively, based on previous reports 22,31-33 . An area under the ROC curve (AUC) from 0.50 to 0.70 represented poor accuracy, from 0.70 to 0.90 moderate accuracy, and more than 0.90 high accuracy. P <0.05 was taken to represent statistical significance. All statistical analyses were performed using JMP 14.0 (SAS Institute Japan, Tokyo, Japan). Results Patient selection, characteristics, and outcome Patient selection based on inclusion and exclusion criteria, characteristics, and outcome are shown in Figure 1 and Tables 1 and Table 2. Among 117 patients identified with FILD, 15 did not meet the study criteria because 14 patients were not observed for more than 1 year and one did not undergo an examination essential for the present study. Eighty-four patients were selected for the study, including 45 (54%) males and 33 (39%) smokers, with a median age of 69.5 (64.4–75.9) years. GAP stages of study patients were stage 0 in 45 with stage I in 39. FILD subtypes of study patients included 34 (40%) connective tissue disease-associated ILD (CTD-ILD), 21 (25%) IPF, 18 (21%) fibrotic hypersensitivity pneumonia (HP), 7 (8%) unclassifiable ILD (UC-ILD), 3 (4%) smoking-related ILD (SR-ILD), and 1 (1%) non-specific interstitial pneumonia. Among 34 patients with CTD-ILD, disease subtypes of CTD consisted of 5 SSc, 8 DM, 8 primary SS, 6 RA, 4 MPA, 1 PM, 1 SSc with secondary SS, and 1 DM with secondary SS. Radiological ILD patterns based on the global IPF guidelines 1 included definite UIP in 14 (17%) patients, probable UIP in 10 (12%), indeterminate for UIP in 15 (18%), and alternative diagnosis in 45 (54%). Annual progression of FILD was present in 31 (37%) of the 84 study patients including more than 10% decrease in FVC in 13 (16%) patients, more than 15% decrease in D LCO in 21 (27%), and developing AE in 1 (1%), with no deaths due to FILD. Among the 84 study patients, 24 (29%), 36 (43%), and 20 (24%) were treated with antifibrotic drugs, corticosteroids, and immunosuppressants over 180 days, respectively. In comparisons of clinical data, the patient group with annual progression included those with significantly higher age and decreased SpO 2 in the 6MWT, more fibrotic HP, definite UIP pattern on CT, and GAP stage I in comparison with the group without annual progression. Similarly, the group with annual progression included patients with significantly lower SpO 2 in the 6MWT, role physical and role emotional in SF-36, less CTD-ILD, and less than 90% of lowest SpO 2 in the 6MWT compared with the group without annual progression. There was no significant difference in the period from diagnosis of FILD to hospitalization for the examination program, and drug exposure over 180 days between patients with and without annual progression of FILD. Analysis of risk factors of annual progression of FILD The results of the analysis of risk factors of annual progression of FILD are shown in Tables 3 and 4. Univariate analysis showed that higher age (odds ratio (OR), 56.4; 95% confidence interval (CI), 3.3–1583.2; standard error (SE), 0.0286; P =0.0041), diagnosis with fibrotic HP (OR, 4.9; 95% CI, 1.7–16.1; SE, 0.285; P =0.036), definite UIP pattern on CT (OR, 3.9; 95% CI, 1.2–14.1; SE, 0.307; P =0.022), GAP stage I (OR, 2.6; 95% CI, 1.1–6.6; SE, 0.234; P =0.036), lowest SpO 2 in the 6MWT (OR, 0.069; 95% CI, 0.0065–0.57; SE, 0.0513; P =0.013), higher decrease in SpO 2 in the 6MWT (OR, 20.2; 95% CI, 2.8–183.9; SE, 0.0480; P =0.0023), and shorter 6MWD (OR, 0.087; 95% CI, 0.0064-0.97; SE, 0.00210; P =0.047) were significantly associated with higher incidence of annual progression of FILD (Tables 3A and 3B). Multivariate analysis, adjusting for some combinations of variables with of P value of <0.10 in univariate analysis and confounding factors, was performed for six logistic regression analyses using backward elimination (Table 4). While selecting variables for each model of the multivariate analysis, the combination of lowest and decrease in SpO 2 in the 6MWT, of diagnosis of IPF and definite UIP pattern on CT, and of GAP stage and component of GAP staging system including age, gender, FVC, D LCO , and ILD subtype, were regarded as covariates in each. The independent predictive factors of higher annual progression of FILD were diagnosis of IPF and fibrotic HP, definite UIP pattern on CT, GAP stage I, lower D LCO , lowest SpO 2 and greater decrease in SpO 2 in the 6MWT, and higher CAT score (Table 4). ROC analysis for predicting annual progression of FILD ROC curves with AUC, cut-off points, and sensitivity and specificity of independent predictive consecutive parameters used to identify patients with annual progression are shown in Figure 2. The discriminatory power of decrease in SpO 2 in the 6MWT (cut-off value, 4%; AUC, 0.713; sensitivity 60%; specificity, 71%) was moderate accuracy, and that of lowest SpO 2 in the 6MWT (cut-off value, 90%; AUC, 0.692; sensitivity 74%; specificity, 55%), D LCO (cut-off value, 40%; AUC, 0.513; sensitivity 6%; specificity, 71%), and CAT (cut-off value, 10; AUC, 0.620; sensitivity 50%; specificity, 71%) was poor accuracy. The present study showed the possibility that a 4% decrease in SpO 2 in the 6MWT is a superior cut-off level for predicting progression of FILD. Discussion This study identified several independent predictors of annual progression in patients with mild FILD with GAP stage 0 or I, including lowest SpO 2 and decrease in SpO 2 in the 6MWT, diagnosis with IPF and fibrotic HP, GAP stage I, D LCO , and higher CAT score. Previous research has established desaturation and reduced walk distance in the 6MWT as predictors of survival in IPF 31–36 . Moreover, desaturation in the 6MWT is reported as a prognostic factor of survival, especially among patients with early FILD. Among IPF patients with more than 80 torr PaO 2 at rest, patients with desaturation in the 6MWT have a significantly worse prognosis than those without desaturation (log-rank test, P =0.0033) 31 . Similarly, among 179 mild-IPF patients with Japanese Respiratory Society disease severity system stage I, patients with desaturation in the 6MWT or with increased GAP staging had significantly shorter survival and higher incidence of disease progression compared with patients without those factors 32 . Additionally, a PubMed literature review of lung function testing in IPF suggested that less than 40% D LCO was associated with worse survival 37 . Dysfunction of gas change demonstrated by measuring desaturation in the 6MWT and D LCO at the early disease stage of FILD can be a potential predictor of annual progression. Definite UIP, one of the CT patterns of ILD, shows high concordance with the pathological UIP pattern 1-2 . Adegunsoye et al. suggested that CT honeycombing, a representative and required feature in definite UIP criteria, was associated with increased mortality among non-IPF-ILD patients regardless of those subgroups (chronic HP, CTD-ILD, and UC-ILD) 38 . By contrast, mortality was similar between those with and without CT honeycombing among IPF 38 . Fibrotic HP is one of the FILD subtypes presenting as an immunologically mediated disease resulting from inhalational exposure to environmental and/or occupational inciting antigens 39-40 . Some studies have shown that a proportion of fibrotic HP patients develop progressive disease characterized by increasing fibrotic abnormalities on CT, worsening lung function, and early mortality at the same rate as IPF 39-41 . For example, a retrospective study showed that 35 of 112 patients (31%) with fibrotic HP had a more than 10% decrease in FVC over a period of 6–12 months 42 . Prognostic factors associated with worse survival included honeycombing or fibrotic lesion on CT, inability to remove the inciting antigen, older age, and male gender 43-44 . To our knowledge, this is the first study to identify CAT score as a predictor of progression in early-stage FILD. The CAT score had previously been associated with survival in advanced FILD patients receiving oxygen therapy 21 . Our findings suggest that CAT, along with 6MWT desaturation and D LCO , can help identify patients with mild FILD who may benefit from early antifibrotic therapy. Accurate diagnosis of ILD subtype and radiological pattern by MDD can further inform treatment decisions. The present study has some limitations. First, the sample size was relatively small, and larger studies are needed to validate our findings. Second, the starting date of annual progression (day 0) was defined as the date of hospitalization for the examination program for FILD, not the day of diagnosis. Nevertheless, during the period from diagnosis day to the starting date of the present study there was no apparent difference between the groups with and without annual progression. Third, while we adjusted for established confounders, other unknown factors may have influenced disease progression. Conclusion In conclusion, this study identified exercise-induced hypoxia, impaired gas change, higher CAT score, GAP stage I, definite UIP pattern on CT, and diagnosis with IPF and fibrotic HP as independent predictors of annual progression in mild FILD. These prognostic factors can help in selecting patients who may benefit from early intervention via antifibrotic therapy, potentially improving outcomes of this challenging disease. Declarations Financial disclosures The study’s expenses were paid from the research funds of Department of Respirology, NHO Kyushu Medical Center. Authors’ contributions M.O. initiated the study and wrote the main manuscript and figure. K.F., T.C., and A.S. contributed to the radiological evaluations in multidisciplinary discussion diagnosis. K.T. and Y.Z. contributed to the pathological evaluations in multidisciplinary discussion diagnosis. A.K. performed the statistical analyses. Y.N. enrolled the cases. M.O. M.T., H.T., N.M., and T.N. performed the data analysis and interpretation. T.Y. and T.H. supervised the research. All authors fulfill the authorship criteria and have read and approved the final version of the manuscript. Acknowledgments We thank Ms. Natsuko Shibata, M.T. of the Department of Respirology, NHO Kyushu Medical Center, for sorting medical data. Conflicts of interest statements Masaki Okamoto, Toyoshi Yanagihara, and Tomoaki Hoshino received more than 1,000,000 JPY as research funding from Nippon Boehringer-Ingelheim, Co., Ltd. Kiminori Fujimoto received more than 1,000,000 JPY as research funding from Micron KK. Masaki Okamoto and Yoshiaki Zaizen received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, Co., Ltd. The other co-authors have no potential conflicts of interest. Availability of data and materials The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Ethics approval and consent to participate We received specific approval for all procedures from the Institutional Review Board (IRB) of NHO Kyushu Medical Center. The approval number (date of IRB approval) of our study is 22C080 (December 21, 2022). All research was performed in accordance with relevant guidelines/regulations. Consent for publication Informed consent was obtained in the form of opt-out methodology for the study period. Informed consent was waived by the Kyushu Medical Center References Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205: e18-e47. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198: e44–e68. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188: 733-748. Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190: 773-779. Khor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ; Austin ILD Registry and CARE-PF Investigators. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions. Am J Respir Crit Care Med. 2023; 207: 102-105. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092. Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest 2021; 160: 1751-1763. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381: 1718-1727. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014; 145: 723-728. Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 2019; 7: 771-779. Kolb M, Flaherty KR, Silva RS, Prasse A, Vancheri C, Mueller H, et al. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics. Adv Ther. 2023; 40: 5536-5546. Ryerson CJ, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, et al. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Res. 2019; 5: 00127–2018. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2013; 65: 2737–2747. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569–2581. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017; 76: 9-16. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021; 73: 1366-1383. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643. Kataoka K, Oda K, Takizawa H, Ogura T, Miyamoto A, Inoue Y, et al. Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy. Sci Rep. 2023; 13: 13664. Venkatesan P. GOLD COPD report: 2024 update. Lancet Respir Med. 2024; 12: 15-16. Yoza Y, Ariyoshi K, Honda S, Taniguchi H, Senjyu H. Development of an activity of daily living scale for patients with COPD: the Activity of Daily Living Dyspnoea scale. Respirology. 2009; 14: 429-435. Mahler DA, Mackowiak JI. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest. 1995; 107: 1585-1589. Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, et al. Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Intern Med. 2017; 56: 1637-1644. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Guideline Am J Respir Crit Care Med. 2002; 166: 111-117. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol. 1982; 33: 379-387. Noda Y. et al. Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer. Sci Rep 2022; 12: 8881. Wong AW, Liang J, Cottin V, Ryerson CJ. Diagnostic Features in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review. Ann Am Thorac Soc. 2020; 17: 1333-1336.. Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Ando M, Murotani K, et al. Disease severity staging system for idiopathic pulmonary fibrosis in Japan. Respirology. 2017; 22: 1609-1614. Sugino K, Ono H, Watanabe N, Ando M, Tsuboi E, Homma S, et al. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC Pulm Med. 2021; 21: 218. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168: 1084-1090. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 36: 1067-1072. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174: 659-664. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 183: 1231-1237. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005; 60: 270-273. Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Chung JH, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019; 16: 580–588. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 202: e36-e69. Fernández Pérez ER, Travis WD, Lynch DA, Brown KK, Johannson KA, Selman M, et al. Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report. Chest. 2021; 160: e97-e156. Alberti ML, Malet Ruiz JM, Fernández ME, Fassola L, Caro F, Roldán IB, Paulin F. Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology. 2020; 26: 3-9. Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018; 73: 391-392. Fernández Pérez ER, Swigris JJ, Forssén AV, Solomon JJ, Huie TJ, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144: 1644–1651. Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest. 2019; 155: 699-711. Tables Table 1A. Patients’ characteristics Annual progression of FILD All cases Yes No P value Number 84 31 (37%) 53 (63%) 0.65 Age (years) 69.5 (64.4-75.9) 72.1 (68.8-76.3) 67.4 (61.0-74.0) 0.0096* Male gender 45 (54%) 18 (58%) 27 (51%) 0.65 Smoker 33 (39%) 12 (39%) 21 (40%) 1 Body mass index (kg/m 2 ) 23.4 (20.6-25.7) 23.3 (20.7-25.7) 23.4 (20.5-25.7) 0.89 FILD subtype IPF 21 (25%) 11 (36%) 10 (19%) 0.12 NSIP 1 (1%) 0 2 (4%) SR-ILD 3 (4%) 0 3 (6%) Fibrotic HP 18 (21%) 12 (39%) 6 (11%) 0.0052* CTD-ILD 34 (40%) 6 (19%) 27 (51%) 0.0054* UC-ILD 7 (8%) 1 (3%) 6 (11%) 0.25 HRCT pattern Definite UIP 14 (17%) 9 (29%) 5 (9 %) 0.0098* Probable UIP 10 (12%) 0 10 (19%) Indeterminate for UIP 15 (18%) 6 (19%) 9 (17%) Alternative diagnosis 45 (54%) 16 (52%) 29 (55%) CT-Goddard score (0-24) 8.0 (6.0-11.0) 8.0 (6.0-11.0) 8.0 (6.0-11.0) 0.69 mMRC scale (0/1/2/3/4) 18 / 43 / 16 / 5 / 2 7 / 14 / 6 / 3 / 1 11 /29 / 10 / 2 / 1 0.75 GAP stage 0 / 1 45 (54%) / 39 (46%) 12 (39%) / 19 (61%) 33 (62%) / 20 (38%) 0.044* Pulmonary function FVC (%) 84.7 (69.4-96.7) 79.8 (65.5-92.9) 88.3 (71.1-99.8) 0.15 D LCO (%) 66.2 (57.9-82.4) 68.6 (56.7-83.8) 65.4 (58.9-81.6) 0.84 Six-months walk test Lowest SpO 2 (%) 91.5 (88.0-94.0) 89.0 (85.0-92.0) 92.0 (89.0-95.0) 0.0034* Less than 90% 31 (37%) 17 (55%) 14 (26%) 0.011* Decrease in SpO 2 (%) 5.0 (3.0-8.0) 7.0 (4.0-10.0) 4.0 (1.9-6.0) 0.0011* More than 4% 55 (65%) 24 (77%) 31 (58%) 0.098 Highest mBorg scale 3 (1-4) 4.0 (1.3-5.0) 2.0 (1.0-4.0) 0.057 Walk distance (m) 390.0 (340.0-487.5) 375.0 (300.0-460.0) 415.0 (342.5-502.5) 0.083 Serum biomarker CRP (mg/dL) 0.11 (0.060-0.32) 0.11 (0.050-0.30) 0.11 (0.060-0.32) 0.77 KL-6 (IU/mL) 880.5 (535.8-1391.5) 876.0 (549.0-1747.0) 929.0 (493.5-1303.5) 0.78 Monocyte counts (/µL) 383.7 (282.6-470.4) 372.4 (279.0-484.8) 387.6 (303.1-466.9) 0.61 Period from FILD diagnosis to admission 57.5 (26.3-609.0) 54.0 (26.0-610.0) 71.0 (26.0-629.0) 0.92 Data are expressed as the median (25th to 75th percentiles of the interquartile range [IQR]), unless otherwise stated. FILD, fibrotic interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; SR-ILD, smoking-related interstitial lung disease; HP, hypersensitivity pneumonia; CTD, connective tissue disease; UC-ILD, unclassifiable interstitial lung disease; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia; mMRC, modified medical research council; GAP, gender-age-physiology; FVC, forced vital capacity; D LCO , diffusing capacity of the lung for carbon monoxide; SpO 2 , saturation of percutaneous oxygen; mBorg, modified Borg; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; * P <0.05 is regarded as statistically significant. Table 1B. Patients’ reported outcomes and muscle strength Annual progression of FILD All cases Yes No P value Number 84 31 (37%) 53 (63%) Patient reported outcome CAT 13 (7-19) 16.0 (9.0-25.0) 10.5 (7.0-17) 0.068 NRADL 93.0 (81.0-98.0) 90.0 (74.8-97.0) 94.0 (85.0-98.0) 0.13 SF-36 Physical function 75.0 (50.0-90.0) 65.0 (50.0-85.0) 80.0 (51.3-93.8) 0.19 Role physical 75.0 (55.5-100.0) 62.5 (43.8-87.5) 87.5 (56.3-100.0) 0.048* Body pain 66.0 (41.0-84.0) 52.0 (36.5-74.0) 72.0 (42.0-84.0) 0.14 General health 50.0 (37.5-57.0) 45.0 (35.0-57.0) 50.0 (40.0-58.5) 0.32 Vitality 56.3 (43.8-68.8) 50.0 (37.5-67.8) 62.3 (45.4-68.8) 0.15 Social function 87.5 (55.0-100.0) 75.0 (50.0-100.0) 87.5 (62.5-100.0) 0.14 Role emotional 83.3 (50.0-100.0) 66.7 (50.0-91.7) 95.9 (60.4-100.0) 0.032* Mental health 70.0 (55.0-80.0) 60.0 (55.0-72.5) 70.0 (55.0-80.0) 0.26 HADS Anxiety 5.0 (2.0-7.0) 5.0 (3.0-7.8) 4.0 (2.0-7.0) 0.13 Depression 6.0 (4.0-8.0) 6.0 (4.0-9.5) 6.0 (4.0-8.0) 0.75 Muscle strength Limb skeletal muscle mass 17.8 (14.8-21.5) 18.0 (14.7-21.4) 17.8 (15.0-22.6) 0.65 Knee extension strength 22.3 (16.7-33.5) 25.1 (18.0-32.7) 23.9 (19.6-30.5) 0.99 Grip strength 23.7 (18.2-31.7) 19.5 (15.5-32.9) 23.6 (19.0-33.9) 0.13 Data are expressed as the median (25th to 75th percentiles of the interquartile range [IQR]), unless otherwise stated. FILD, fibrotic interstitial lung disease; CAT, chronic obstructive pulmonary disease assessment test; NRADL, the Nagasaki University Respiratory Activities of Daily Living Questionnaire; SF-36, Short Form 36; HADS, Hospital Anxiety and Depression Scale. * P <0.05 is regarded as statistically significant. Table 2. Patients’ outcome Annual progression of FILD All cases Yes No P value Number 84 31 (37%) 53 (63%) Component of annual progression of FILD More than 10% decrease in FVC 13 (16%) 13 (42%) 0 More than 15% decrease in D LCO 21 (27%) 21 (68%) 0 Developing acute exacerbation 1 (1%) 1 (3%) 0 Mortality due to FILD 0 0 0 Exposure of drug therapy Antifibrotic drug 24 (29%) 11 (36%) 13 (25%) 0.32 Nintedanib 33 (39%) 10 (32%) 13 (25%) 0.46 Pirfenidone 1 (1%) 1 (3%) 0 0.37 Immunosuppressive therapy 40 (48%) 11 (36%) 29 (55%) 0.11 Corticosteroid 36 (43%) 11 (36%) 25 (47%) 0.36 Immunosuppressant 20 (24%) 4 (13%) 16 (30%) 0.11 Data are expressed as the median (25th to 75th percentiles of the interquartile range [IQR]), unless otherwise stated. FILD, fibrotic interstitial lung disease; FVC, forced vital capacity; D LCO , diffusing capacity of the lung for carbon monoxide. * P <0.05 is regarded as statistically significant. Table 3. Univariate analysis of factors associated with disease progression using the logistic regression analysis Part 1 OR 95%CI SE P value Age (years) 56.4 3.3-1583.2 0.0286 0.0041* Male gender 1.3 0.55-3.3 0.228 0.53 Smoker 1.0 0.42-2.6 0.232 0.93 Body mass index(kg/m 2 ) 0.73 0.078-6.6 0.0580 0.78 ILD subtype IPF 2.4 0.86-6.6 0.257 0.094 Fibrotic HP 4.9 1.7-16.1 0.285 0.036* CTD-ILD 0.23 0.075-0.62 0.266 0.0033* UC-ILD 0.26 0.013-1.6 0.547 0.17 Definite pattern on CT 3.9 1.2-14.1 0.307 0.022* CT-Goddard score (0-24) 1.5 0.20-11.6 0.0853 0.69 mMRC grade (0/1/2/3/4) 2.0 0.28-14.3 0.2470 0.48 GAP stage I 2.6 1.1-6.6 0.234 0.036* Pulmonary function FVC (%) 0.26 0.033-1.8 0.0124 0.18 D LCO (%) 1.5 0.14-16.1 0.0126 0.74 Six-months walk test Lowest SpO 2 (%) 0.069 0.0065-0.57 0.0513 0.013* Highest mBorg scale 5.6 0.89-39.1 0.1060 0.066 Decrease in SpO 2 20.2 2.8-183.9 0.0480 0.0023* Walk distance (m) 0.087 0.0064-0.97 0.00210 0.047* Serum biomarker CRP (mg/dL) 0.13 0.0011-2.2 0.518 0.18 KL-6 (IU/mL) 1.9 0.29-12.7 0.000194 0.48 Monocyte counts (/µL) 0.041 4.073e-5-5.0 0.116 0.23 OR, odds ratio; SE, standard error; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; HP, hypersensitivity pneumonia; CTD, connective tissue disease; UC-ILD, unclassifiable interstitial lung disease; UIP, usual interstitial pneumonia; mMRC, modified Medical Research Council; GAP, gender-age-physiology; FVC, forced vital capacity; D LCO , diffusing capacity of the lung for carbon monoxide; mBorg, modified Borg; SpO 2 , saturation of percutaneous oxygen; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6. * P <0.05 is regarded as statistically significant. B . Part 2 OR 95%CI SE P value Patient reported outcome CAT 6.9 0.98-55.4 0.0261 0.052 NRADL 0.25 0.023-2.5 0.0156 0.24 SF-36 Physical function 0.38 0.061-2.3 0.00911 0.28 Role physical 0.25 0.048-1.2 0.00814 0.086 Body pain 0.30 0.053-1.6 0.00867 0.16 General health 0.16 0.011-2.0 0.0144 0.16 Vitality 0.28 0.033-2.2 0.0113 0.23 Social function 0.29 0.050-1.6 0.00866 0.15 Role emotional 0.36 0.075-1.6 0.00775 0.18 Mental health 0.19 0.015-2.2 0.0126 0.18 HADS-A 8.0 0.60-131.8 0.0797 0.12 HADS-D 3.0 0.25-37.2 0.0738 0.39 Muscle strength Limb skeletal muscle mass 0.51 0.053-4.3 0.0539 0.54 Knee extension strength 0.14 0.0087-1.6 0.0224 0.12 Grip strength 1.1 0.11-10.1 0.0254 0.94 Drug exposure more than 180 days Antifibrotic drug 1.7 0.64-4.5 0.246 0.29 Immunosuppressive therapy 0.34 0.090-1.1 0.3070 0.063 OR, odds ratio; SE, standard error; CAT, chronic obstructive pulmonary disease assessment test; NRADL, the Nagasaki University Respiratory Activities of Daily Living Questionnaire; SF-36, Short Form 36; HADS-A, Hospital Anxiety and Depression Scale–Anxiety; HADS-D, Hospital Anxiety and Depression Scale–Depression. * P <0.05 is regarded as statistically significant. Table 4. Multivariate analysis of factors associated with overall survival using the logistic regression analyses Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Age (years) N.S. N.S. N.S. N.S. N.S. N.S. Gender Male N.S. N.S. N.S. N.S. N.S. N.S. IPF N.S. N.S. N.S. 12.2 (2.9-62.7) P=0.0019* N.S. Fibrotic HP 17.1 (3.7-107.8) P=0.00010* 17.1 (3.7-107.8) P=0.00010* 18.8 (4.2-115.1) P<0.00010* 17.1 (3.7-107.8) P=0.00010* 8.5 (2.2-39.7) P=0.00040* 9.6 (2.5-43.8) P=0.00080* CTD-ILD N.S. N.S. N.S. N.S. N.S. N.S. CT-definite UIP pattern 7.2 (1.4-44.7) P=0.020* 7.2 (1.4-44.7) P=0.020* 7.5 (1.5-44.0) P=0.013* 7.2 (1.4-44.7) P=0.020* 12.0 (2.6-69.5) P=0.0014* CT-Goddard score (%) N.S. N.S. N.S. N.S. N.S. N.S. FVC (%) N.S. N.S. N.S. N.S. N.S. N.S. D LCO (%) 607.3 (8.8-112270.1) P=0.0022* 607.3 (8.8-112270.1) P=0.0022* 173.3 (3.8-17780.6) P=0.0072* 607.3 (8.8-112270.1) P=0.0022* 362.0 (7.3-42343.1) P=0.0025* 237.1 (5.1-24728.6) P=0.0044* GAP stage I 4.9 (1.2-25.9) P=0.029* 4.9 (1.2-25.9) P=0.029* 4.8 (1.2-24.4) P=0.026* 4.9 (1.2-25.9) P=0.029* N.S. 6MWT-lowest SpO 2 (%) N.S. 0.016 (0.00034-0.41) P=0.0012* N.S. N.S. N.S. 6MWT-decrease in SpO 2 (%) 140.8 (5.5-6424.7) P=0.0021* 140.8 (5.5-6424.7) P=0.0021* 140.8 (5.5-6424.7) P=0.0021* 123.1 (6.0-4403.2) P=0.0013* 111.1 (5.5-3519.7) P=0.0037* 6MWT-highest mBorg scale N.S. N.S. N.S. N.S. N.S. N.S. 6MWD (m) N.S. N.S. N.S. N.S. N.S. N.S. CAT 36.0 (2.0-1021.1) P=0.014* 36.0 (2.0-1021.1) P=0.014* 23.0 (1.5-492.9) P=0.024* 36.0 (2.0-1021.1) P=0.014* 76.5 (4.4-2161.5) P=0.0024* 54.3 (3.2-1425.2) P=0.0048* SF-36 Role Physical N.S. N.S. N.S. N.S. N.S. N.S. Antifibrotic drug use N.S. N.S. N.S. N.S. N.S. N.S. Immunosuppressive therapy N.S. N.S. N.S. N.S. N.S. N.S. Upper row, odds ratio (95% confidence interval); lower row, P value; SE, standard error; IPF, idiopathic pulmonary fibrosis; HP, hypersensitivity pneumonia; CTD, connective tissue disease; UC-ILD, unclassifiable interstitial lung disease; CT, computed tomography; UIP, usual interstitial pneumonia; FVC, forced vital capacity; D LCO , diffusing capacity of the lung for carbon monoxide; GAP, gender-age-physiology; 6MWT, 6-minute walk test; SpO 2 , saturation of percutaneous oxygen; mBorg, modified Borg; CAT, chronic obstructive pulmonary disease assessment test; SF-36, Short Form 36. * P <0.05 is regarded as statistically significant Additional Declarations Competing interest reported. Masaki Okamoto, Toyoshi Yanagihara, and Tomoaki Hoshino received more than 1,000,000 JPY as research funding from Nippon Boehringer-Ingelheim, Co., Ltd. Kiminori Fujimoto received more than 1,000,000 JPY as research funding from Micron KK. Masaki Okamoto and Yoshiaki Zaizen received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, Co., Ltd. The other co-authors have no potential conflicts of interest. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-4513072\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":true,\"archivedVersions\":[],\"articleType\":\"Article\",\"associatedPublications\":[],\"authors\":[{\"id\":315557367,\"identity\":\"04c8f133-9b6d-42b5-8060-ab0deadf707e\",\"order_by\":0,\"name\":\"Masaki Okamoto\",\"email\":\"data:image/png;base64,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\",\"orcid\":\"\",\"institution\":\"Department of Respirology, NHO Kyushu Medical Center\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Masaki\",\"middleName\":\"\",\"lastName\":\"Okamoto\",\"suffix\":\"\"},{\"id\":315557369,\"identity\":\"aaca105d-6e54-4cac-b2bb-e2861b6a09f4\",\"order_by\":1,\"name\":\"Kiminori Fujimoto\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Radiology, Kurume University School of Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Kiminori\",\"middleName\":\"\",\"lastName\":\"Fujimoto\",\"suffix\":\"\"},{\"id\":315557371,\"identity\":\"c00db73f-2184-4249-9b5c-09bef5181ab9\",\"order_by\":2,\"name\":\"Tomonori Chikasue\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Radiology, Kurume University School of Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Tomonori\",\"middleName\":\"\",\"lastName\":\"Chikasue\",\"suffix\":\"\"},{\"id\":315557372,\"identity\":\"86dfc384-1b89-4769-90bd-9d3b0bd35d27\",\"order_by\":3,\"name\":\"Toyoshi Yanagihara\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Respiratory Medicine, Fukuoka University Hospital\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Toyoshi\",\"middleName\":\"\",\"lastName\":\"Yanagihara\",\"suffix\":\"\"},{\"id\":315557373,\"identity\":\"8abb7f0f-41c8-43f7-8791-3552c08525ba\",\"order_by\":4,\"name\":\"Kazuhiro Tabata\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Kazuhiro\",\"middleName\":\"\",\"lastName\":\"Tabata\",\"suffix\":\"\"},{\"id\":315557374,\"identity\":\"33734467-b94a-4f05-abda-557a26ed9917\",\"order_by\":5,\"name\":\"Yoshiaki Zaizen\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Yoshiaki\",\"middleName\":\"\",\"lastName\":\"Zaizen\",\"suffix\":\"\"},{\"id\":315557376,\"identity\":\"6d401255-ea63-4946-b917-9964e5846f01\",\"order_by\":6,\"name\":\"Masaki Tominaga\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Masaki\",\"middleName\":\"\",\"lastName\":\"Tominaga\",\"suffix\":\"\"},{\"id\":315557379,\"identity\":\"87379abf-08b6-4806-bbc5-851d4376f46b\",\"order_by\":7,\"name\":\"Akiko Sumi\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Radiology, Kurume University School of Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Akiko\",\"middleName\":\"\",\"lastName\":\"Sumi\",\"suffix\":\"\"},{\"id\":315557380,\"identity\":\"54594987-c467-40b3-b21a-4d378d7dc3a9\",\"order_by\":8,\"name\":\"Hiroaki Takeoka\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Respirology, NHO Kyushu Medical Center\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Hiroaki\",\"middleName\":\"\",\"lastName\":\"Takeoka\",\"suffix\":\"\"},{\"id\":315557382,\"identity\":\"5ab86430-7839-4d6f-826b-9c54e11f8b53\",\"order_by\":9,\"name\":\"Norikazu Matsuo\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Respirology, NHO Kyushu Medical Center\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Norikazu\",\"middleName\":\"\",\"lastName\":\"Matsuo\",\"suffix\":\"\"},{\"id\":315557387,\"identity\":\"b70dafa7-0f15-4506-99d5-f43cc9091a98\",\"order_by\":10,\"name\":\"Takashi Nouno\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Department of Respirology, NHO Kyushu Medical Center\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Takashi\",\"middleName\":\"\",\"lastName\":\"Nouno\",\"suffix\":\"\"},{\"id\":315557390,\"identity\":\"0f200892-3054-43a9-bf8e-793eaf16c7e1\",\"order_by\":11,\"name\":\"Atsushi Kawaguchi\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Education and Research Center for Community Medicine, Faculty of Medicine, Saga Medical School\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Atsushi\",\"middleName\":\"\",\"lastName\":\"Kawaguchi\",\"suffix\":\"\"},{\"id\":315557391,\"identity\":\"e1311757-b5a5-42ef-9139-1ab14e1a833d\",\"order_by\":12,\"name\":\"Tomoaki Hoshino\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Tomoaki\",\"middleName\":\"\",\"lastName\":\"Hoshino\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2024-06-01 10:01:01\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-4513072/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-4513072/v1\",\"draftVersion\":[],\"editorialEvents\":[],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":59136943,\"identity\":\"88f82a17-6fa8-4533-a6fc-066ca672236e\",\"added_by\":\"auto\",\"created_at\":\"2024-06-26 18:56:38\",\"extension\":\"png\",\"order_by\":1,\"title\":\"Figure 1\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":19255,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e\\u003cstrong\\u003eInclusion and exclusion criteria of the study.\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eFILD, fibrosing interstitial pneumonia; GAP, gender-age-physiology.\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"1.png\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4513072/v1/f480055ddc660a5d266e1f1f.png\"},{\"id\":59136944,\"identity\":\"a98ac534-489a-4b32-b5de-f496e71afc9a\",\"added_by\":\"auto\",\"created_at\":\"2024-06-26 18:56:38\",\"extension\":\"png\",\"order_by\":2,\"title\":\"Figure 2\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":482477,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e\\u003cstrong\\u003eReceiver-operating characteristic analysis.\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eROC curves of independent predictive continuous parameters predicting annual progression of FILD defined as more than 10% decrease in FVC or 15% decrease in D\\u003csub\\u003eLCO\\u003c/sub\\u003e, developing acute exacerbation, and ILD-related death are shown as follows: lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e (A) and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e (B) in the 6MWT, D\\u003csub\\u003eLCO\\u003c/sub\\u003e (C), and CAT (D). The cut-off levels of lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e, D\\u003csub\\u003eLCO\\u003c/sub\\u003e, and CAT were set as less than 90%, 4%, 40%, and 10, respectively, based on the previous reports.\\u003c/p\\u003e\\n\\u003cp\\u003eROC, receiver-operating characteristic; AUC, area under the ROC curve; FILD, fibrosing interstitial lung disease; FVC, forced vital capacity; D\\u003csub\\u003eLCO\\u003c/sub\\u003e, diffusing capacity of the lung for carbon monoxide; 6MWT, 6-minute walk test; CAT, chronic obstructive pulmonary disease assessment test; IPF, idiopathic pulmonary fibrosis. *\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant.\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"2.png\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4513072/v1/4f7bf67fe79180b501353f10.png\"},{\"id\":59826301,\"identity\":\"b8193781-6cf9-453a-a8da-bcf4eacd8115\",\"added_by\":\"auto\",\"created_at\":\"2024-07-08 05:59:14\",\"extension\":\"pdf\",\"order_by\":0,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":1659022,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"manuscript.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4513072/v1/d8d09c2f-b431-457a-b025-6ec09c30ebaf.pdf\"}],\"financialInterests\":\"Competing interest reported. Masaki Okamoto, Toyoshi Yanagihara, and Tomoaki Hoshino received more than 1,000,000 JPY as research funding from Nippon Boehringer-Ingelheim, Co., Ltd.\\nKiminori Fujimoto received more than 1,000,000 JPY as research funding from Micron KK.\\nMasaki Okamoto and Yoshiaki Zaizen received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, Co., Ltd.\\nThe other co-authors have no potential conflicts of interest.\",\"formattedTitle\":\"Predictive factors of progression in fibrosing interstitial lung disease patients with gender-age-physiology stage 0 or I\",\"fulltext\":[{\"header\":\"Introduction\",\"content\":\"\\u003cp\\u003eThe comprehensive disease term \\u0026ldquo;fibrosing interstitial lung disease\\u0026rdquo; (FILD) includes various subtypes of radiological and histopathological lung parenchymal fibrosis with or without inflammation\\u003csup\\u003e1\\u0026ndash;4\\u003c/sup\\u003e. Among the idiopathic interstitial pneumonias (IIPs), idiopathic pulmonary fibrosis (IPF), pathologically defined as usual interstitial pneumonia (UIP), is the most prevalent and has no known cause\\u003csup\\u003e1\\u0026ndash;4\\u003c/sup\\u003e. IPF carries a poor prognosis, with patients having a median survival of only about 3 years\\u003csup\\u003e5\\u003c/sup\\u003e. Non-IPF-FILD patients with progressive characteristics, defined as progressive pulmonary fibrosis by global guidelines and various studies, have similarly grave survival as IPF\\u003csup\\u003e1,6\\u003c/sup\\u003e. In recent years two antifibrotic agents, nintedanib and pirfenidone, have demonstrated safety and efficacy in the treatment for IPF\\u003csup\\u003e7,8\\u003c/sup\\u003e. Nintedanib, in particular, was shown to slow the decline in forced vital capacity (FVC) and reduced the incidence of acute exacerbation (AE) in IPF patients in two replicate randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2)\\u003csup\\u003e7\\u003c/sup\\u003e. Furthermore, a meta-analysis of 12,956 patients with IPF from eight randomized controlled trials and 18 cohort studies revealed that treatment with antifibrotic drugs, including nintedanib and pirfenidone, lowered the risk of all-cause mortality and AE\\u003csup\\u003e9\\u003c/sup\\u003e. More recently, the INBUILD phase 3 trial reported that nintedanib slowed the decline of FVC over 52 weeks in patients with non-IPF FILD with progressive fibrosis\\u003csup\\u003e10\\u003c/sup\\u003e.\\u003c/p\\u003e\\n\\u003cp\\u003eThe interstitial lung disease gender-age-physiology (ILD-GAP) staging system is a promising staging tool for assessing disease severity in accordance with the GAP score, which predicts IPF patient survival based on multiple factors as reported previously, i.e., classifying patients into three stages based on clinical (e.g., gender or age) and physiological (e.g., FVC and diffusing capacity of the lung for carbon monoxide (D\\u003csub\\u003eLCO\\u003c/sub\\u003e)) variables\\u003csup\\u003e11\\u003c/sup\\u003e. The GAP stage is regarded as a well-validated system for classifying the severity of FILD, because as a system it is strongly associated with mortality; for example, 3-year predicted mortality is 10.2% in stage 0 (score 0\\u0026ndash;1), 26.9% in stage I (score 2\\u0026ndash;3), 49.2% in stage II (score 4\\u0026ndash;5), and 74.8% in stage III (score\\u0026nbsp;\\u0026ge;6)\\u003csup\\u003e11\\u003c/sup\\u003e. The GAP stage was believed to contribute to decision-making regarding treatment for FILD including drug therapy, lung transplantation, and palliative care\\u003csup\\u003e11\\u003c/sup\\u003e. For example, patients with GAP stage 0 or I will only occasionally be referred for drug therapy. However, effectiveness of treatment with antifibrotic drugs for early FILD patients has been reported recently\\u003csup\\u003e12,13\\u003c/sup\\u003e. In INMARK, a phase 3 trial for mild-IPF patients with more than 80% FVC, nintedanib suppressed the decline in FVC over 12 weeks\\u003csup\\u003e12\\u003c/sup\\u003e. In the INBUILD trial, nintedanib suppressed the decrease in FVC over 52 weeks regardless of GAP stage and baseline FVC\\u003csup\\u003e10,13\\u003c/sup\\u003e. Similarly, a subgroup analysis of the INPULSIS trials suggested no difference in the effect of nintedanib on FVC decline between patients with GAP stage I and those with GAP stage II/III at baseline\\u003csup\\u003e14\\u003c/sup\\u003e.\\u003c/p\\u003e\\n\\u003cp\\u003eHowever, early intervention with antifibrotic drugs in a proportion of patients with mild FILD may lead to excessive side effects and economic burden. The effectiveness and safety of early intervention with antifibrotic drugs in FILD patients remain uncertain. To identify patients with mild FILD who may benefit from early intervention, it is crucial to determine predictive factors of the outcome.\\u003c/p\\u003e\\n\\u003cp\\u003eIn the present study, we aimed to analyze prognostic factors in patients with mild FILD with GAP stage 0 or I to better inform treatment decisions and optimize patient outcomes.\\u003c/p\\u003e\"},{\"header\":\"Patients and methods\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003ePatient selection\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eIn the present study, we retrospectively analyzed consecutive patients with FILD who underwent a hospitalization examination program for FILD from 2019 to 2022. The inclusion criteria for analysis were as follows: patients diagnosed with FILD according to multidisciplinary discussion (MDD) based on global guidelines of IPF, IIPs, systemic sclerosis (SSc), polymyositis (PM), rheumatoid arthritis (RA), Sj\\u0026ouml;gren\\u0026rsquo;s syndrome (SS), and microscopic polyangiitis (MPA)\\u003csup\\u003e1\\u0026ndash;4,15\\u0026ndash;19\\u003c/sup\\u003e; and patients with GAP stage 0 (score 0 or 1) or I (score 2 or 3) as previously reported \\u003csup\\u003e11\\u003c/sup\\u003e. Exclusion criteria were as follows: patients who could not regularly visit our hospital at least 1 year after hospitalization for the examination program; and patients who could not undergo a pulmonary function test at least every 6 months. Diagnosis of AE of IPF was defined in accordance with the criteria detailed in a previous report\\u003csup\\u003e20\\u003c/sup\\u003e.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eStudy protocol\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eClinical data at hospitalization for the examination program were collected to determine factors predicting progression of FILD. Annual progression of FILD was defined as more than 10% decrease in FVC or 15% decrease in D\\u003csub\\u003eLCO\\u003c/sub\\u003e, developing AE, or death during hospitalization for the examination program. Patients\\u0026rsquo; outcome measures including chronic obstructive pulmonary disease assessment test (CAT)\\u003csup\\u003e21,22\\u003c/sup\\u003e,\\u0026nbsp;the Nagasaki University Respiratory Activities of Daily Living Questionnaire (NRADL)\\u003csup\\u003e23\\u003c/sup\\u003e, Short Form 36 (SF-36)\\u003csup\\u003e24\\u003c/sup\\u003e, Hospital Anxiety and Depression Scale\\u0026ndash;Anxiety (HADS-A) and HADS\\u0026ndash;depression (HADS-D)\\u003csup\\u003e25\\u003c/sup\\u003e, limb skeletal muscle mass, knee extension strength, and grip strength were measured for evaluation of respiratory symptoms. Activities of daily living, health-related quality of life, the psychological condition, and muscle strength were evaluated at hospitalization for the examination program. Overall survival (OS) was measured from the day of hospitalization for the examination program to the final observation day (February 24, 2024).\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003ePulmonary function tests\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003ePulmonary function tests, including FVC and forced expiratory volume in 1 second, were performed using an electronic spirometer. The D\\u003csub\\u003eLCO\\u003c/sub\\u003e was measured using the single-breath technique. These tests were performed according to the guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS)\\u003csup\\u003e26\\u003c/sup\\u003e.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eSix-minute walk test\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe 6-minute walk test (6MWT) was performed according to the ATS statement\\u003csup\\u003e27\\u003c/sup\\u003e. Patients were instructed to walk as fast as possible and were allowed to slow down or stop if necessary during examination.\\u0026nbsp;saturation of percutaneous oxygen\\u0026nbsp;(SpO\\u003csub\\u003e2\\u003c/sub\\u003e), heart rate, modified Borg (mBorg) scale, and 6-minute walk distance (6MWD) were monitored and recorded.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eCT assessment of emphysema (CT-Goddard score)\\u003c/em\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eAll CT examinations were performed using a 128-channel MDCT (Aquilion ONE ViSION\\u0026reg;, Cannon Medical Systems, Japan). To evaluate pulmonary emphysema in both lungs, CT images with 1.0-mm slice thickness were reconstructed at intervals of 1.0 mm. The CT images of each patient were transferred to a workstation with the Synapse Vincent (Fujifilm Medical, Tokyo, Japan). According to the corresponding Goddard classification\\u003csup\\u003e28\\u003c/sup\\u003e, the entire field of each lung was divided into three areas (levels of the aortic arch, the carina, and the upper end of the diaphragm), with a total of six areas for both sides. Areas of low attenuation less than\\u0026nbsp;\\u0026ndash;\\u0026nbsp;950 Hounsfield unit were considered to indicate emphysema\\u003csup\\u003e29\\u003c/sup\\u003e. Thereafter, the severity of emphysema was scored using a 5-point scale for each area as follows: emphysema extending to \\u0026lt; 5% of the area scored 0 points; \\u0026ge; 5% and \\u0026lt; 25%, 1 point; \\u0026ge; 25% and \\u0026lt; 50%, 2 points; \\u0026ge; 50% and \\u0026lt; 75%, 3 points; and \\u0026ge; 75%, 4 points. The total points from all six areas for each patient were calculated as a CT-Goddard score ranging from 0 to 24.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eStatistical analysis\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eData are expressed as the median (25th\\u0026ndash;75th percentiles of the interquartile range). For comparison of clinical data between two groups, we used the Wilcoxon rank-sum test and Fisher\\u0026rsquo;s exact test\\u0026nbsp;as appropriate. In the logistic regression analysis using backward elimination, we detected variables associated with annual progression of FILD by univariate analyses and multivariate analysis, adjusting for covariates with prognosis including age, gender, FVC, D\\u003csub\\u003eLCO\\u003c/sub\\u003e, diagnosis of IPF, and immunosuppressive therapy including corticosteroids or immunosuppressants for more than 180 days, and covariates with desaturation as Goddard score based on previous reports\\u003csup\\u003e1\\u0026ndash;4,11,30\\u003c/sup\\u003e. \\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.10 in univariate analysis was set as the criterion for multivariate analysis. The cut-off levels of lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e, D\\u003csub\\u003eLCO\\u003c/sub\\u003e, and CAT by receiver-operating characteristic (ROC) curve analysis were set as 90%, 4%, 40%, and 10, respectively, based on previous reports\\u003csup\\u003e22,31-33\\u003c/sup\\u003e. An area under the ROC curve (AUC) from 0.50 to 0.70 represented poor accuracy, from 0.70 to 0.90 moderate accuracy, and more than 0.90 high accuracy. \\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 was taken to represent statistical significance. All statistical analyses were performed using JMP 14.0 (SAS Institute Japan, Tokyo, Japan).\\u003c/p\\u003e\"},{\"header\":\"Results\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003ePatient selection, characteristics, and outcome\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003ePatient selection based on inclusion and exclusion criteria, characteristics, and outcome are shown in Figure 1 and Tables 1 and Table 2. Among 117 patients identified with FILD, 15 did not meet the study criteria because 14 patients were not observed for more than 1 year and one did not undergo an examination essential for the present study. Eighty-four patients were selected for the study, including 45 (54%) males and 33 (39%) smokers, with a median age of 69.5 (64.4\\u0026ndash;75.9) years. GAP stages of study patients were stage 0 in 45 with stage I in 39. FILD subtypes of study patients included 34 (40%) connective tissue disease-associated ILD (CTD-ILD), 21 (25%) IPF, 18 (21%) fibrotic hypersensitivity pneumonia (HP), 7 (8%) unclassifiable ILD (UC-ILD), 3 (4%) smoking-related ILD (SR-ILD), and\\u0026nbsp;1 (1%) non-specific interstitial pneumonia.\\u0026nbsp;Among 34 patients with CTD-ILD, disease subtypes of CTD consisted of 5 SSc, 8 DM, 8 primary SS, 6 RA, 4 MPA, 1 PM, 1 SSc with secondary SS, and 1 DM with secondary SS.\\u0026nbsp;Radiological ILD patterns based on the global IPF guidelines\\u003csup\\u003e1\\u003c/sup\\u003e included definite UIP in 14 (17%) patients, probable UIP in 10 (12%), indeterminate for UIP in 15 (18%), and alternative diagnosis in 45 (54%). Annual progression of FILD was present in 31 (37%) of the 84 study patients including more than 10% decrease in FVC in 13 (16%) patients, more than 15% decrease in D\\u003csub\\u003eLCO\\u003c/sub\\u003e in 21 (27%), and developing AE in 1 (1%), with no deaths due to FILD. Among the 84 study patients, 24 (29%), 36 (43%), and 20 (24%) were treated with antifibrotic drugs, corticosteroids, and immunosuppressants over 180 days, respectively. In comparisons of clinical data, the patient group with annual progression included those with significantly higher age and decreased SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT, more fibrotic HP, definite UIP pattern on CT, and GAP stage I in comparison with the group without annual progression. Similarly, the group with annual progression included patients with significantly lower SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT, role physical and role emotional in SF-36, less CTD-ILD, and less than 90% of lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT compared with the group without annual progression. There was no significant difference in the period from diagnosis of FILD to hospitalization for the examination program, and drug exposure over 180 days between patients with and without annual progression of FILD.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAnalysis of risk factors of annual progression of FILD\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe results of the analysis of risk factors of annual progression of FILD are shown in Tables 3 and 4. Univariate analysis showed that higher age (odds ratio (OR), 56.4; 95% confidence interval (CI), 3.3\\u0026ndash;1583.2; standard error (SE), 0.0286; \\u003cem\\u003eP\\u003c/em\\u003e=0.0041), diagnosis with fibrotic HP (OR, 4.9; 95% CI, 1.7\\u0026ndash;16.1; SE, 0.285; \\u003cem\\u003eP\\u003c/em\\u003e=0.036), definite UIP pattern on CT (OR, 3.9; 95% CI, 1.2\\u0026ndash;14.1; SE, 0.307; \\u003cem\\u003eP\\u003c/em\\u003e=0.022), GAP stage I (OR, 2.6; 95% CI, 1.1\\u0026ndash;6.6; SE, 0.234; \\u003cem\\u003eP\\u003c/em\\u003e=0.036), lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT (OR, 0.069; 95% CI, 0.0065\\u0026ndash;0.57; SE, 0.0513; \\u003cem\\u003eP\\u003c/em\\u003e=0.013), higher decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT (OR, 20.2; 95% CI, 2.8\\u0026ndash;183.9; SE, 0.0480; \\u003cem\\u003eP\\u003c/em\\u003e=0.0023), and shorter 6MWD (OR, 0.087; 95% CI, 0.0064-0.97; SE, 0.00210; \\u003cem\\u003eP\\u003c/em\\u003e=0.047) were significantly associated with higher incidence of annual progression of FILD (Tables 3A and 3B). Multivariate analysis, adjusting for some combinations of variables with of P value of \\u0026lt;0.10 in univariate analysis and confounding factors, was performed for six logistic regression analyses using backward elimination (Table 4). While selecting variables for each model of the multivariate analysis, the combination of lowest and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT, of diagnosis of IPF and definite UIP pattern on CT, and of GAP stage and component of GAP staging system including age, gender, FVC, D\\u003csub\\u003eLCO\\u003c/sub\\u003e, and ILD subtype, were regarded as covariates in each. The independent predictive factors of higher annual progression of FILD were diagnosis of IPF and fibrotic HP, definite UIP pattern on CT, GAP stage I, lower D\\u003csub\\u003eLCO\\u003c/sub\\u003e, lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e and greater decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT, and higher CAT score (Table 4).\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eROC analysis for predicting annual progression of FILD\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eROC curves with AUC, cut-off points, and sensitivity and specificity of independent predictive consecutive parameters used to identify patients with annual progression are shown in Figure 2. The discriminatory power of decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT (cut-off value, 4%; AUC, 0.713; sensitivity 60%; specificity, 71%) was moderate accuracy, and that of lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT (cut-off value, 90%; AUC, 0.692; sensitivity 74%; specificity, 55%), D\\u003csub\\u003eLCO\\u003c/sub\\u003e (cut-off value, 40%; AUC, 0.513; sensitivity 6%; specificity, 71%), and CAT (cut-off value, 10; AUC, 0.620; sensitivity 50%; specificity, 71%) was poor accuracy. The present study showed the possibility that a 4% decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT is a superior cut-off level for predicting progression of FILD.\\u003c/p\\u003e\"},{\"header\":\"Discussion\",\"content\":\"\\u003cp\\u003eThis study identified several independent predictors of annual progression in patients with mild FILD with GAP stage 0 or I, including lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT, diagnosis with IPF and fibrotic HP, GAP stage I, D\\u003csub\\u003eLCO\\u003c/sub\\u003e, and higher CAT score.\\u003c/p\\u003e\\n\\u003cp\\u003ePrevious research has established desaturation and reduced walk distance in the 6MWT as predictors of survival in IPF\\u003csup\\u003e31\\u0026ndash;36\\u003c/sup\\u003e. Moreover, desaturation in the 6MWT is reported as a prognostic factor of survival, especially among patients with early FILD. Among IPF patients with more than 80 torr PaO\\u003csub\\u003e2\\u003c/sub\\u003e\\u0026thinsp;at rest, patients with desaturation in the 6MWT have a significantly worse prognosis than those without desaturation (log-rank test, \\u003cem\\u003eP\\u003c/em\\u003e=0.0033)\\u003csup\\u003e31\\u003c/sup\\u003e. Similarly,\\u0026nbsp;among 179 mild-IPF patients with Japanese Respiratory Society disease severity system stage I,\\u0026nbsp;patients with desaturation in the 6MWT or with increased GAP staging had significantly shorter survival and higher incidence of disease progression compared with patients without those factors\\u003csup\\u003e32\\u003c/sup\\u003e.\\u0026nbsp;Additionally, a PubMed literature review of lung function testing in IPF suggested that less than 40% D\\u003csub\\u003eLCO\\u003c/sub\\u003e was associated with worse survival\\u003csup\\u003e37\\u003c/sup\\u003e. Dysfunction of gas change demonstrated by measuring desaturation in the 6MWT and D\\u003csub\\u003eLCO\\u003c/sub\\u003e at the early disease stage of FILD can be a potential predictor of annual progression.\\u003c/p\\u003e\\n\\u003cp\\u003eDefinite UIP, one of the CT patterns of ILD, shows high concordance with the pathological UIP pattern\\u003csup\\u003e1-2\\u003c/sup\\u003e. Adegunsoye et al. suggested that CT honeycombing, a representative and required feature in definite UIP criteria, was associated with increased mortality among non-IPF-ILD patients regardless of those subgroups (chronic HP, CTD-ILD, and UC-ILD)\\u003csup\\u003e38\\u003c/sup\\u003e. By contrast, mortality was similar between those with and without CT honeycombing among IPF\\u003csup\\u003e38\\u003c/sup\\u003e. Fibrotic HP is one of the FILD subtypes presenting as an immunologically mediated disease resulting from inhalational exposure to environmental and/or occupational inciting antigens\\u003csup\\u003e39-40\\u003c/sup\\u003e. Some studies have shown that a proportion of fibrotic HP patients develop progressive disease characterized by increasing fibrotic abnormalities on CT, worsening lung function, and early mortality at the same rate as IPF\\u003csup\\u003e39-41\\u003c/sup\\u003e.\\u0026nbsp;For example, a retrospective study showed that 35 of 112 patients (31%) with fibrotic HP had a more than 10% decrease in FVC over a period of 6\\u0026ndash;12 months\\u003csup\\u003e42\\u003c/sup\\u003e. Prognostic factors associated with worse survival included honeycombing or fibrotic lesion on CT, inability to remove the inciting antigen, older age, and male gender\\u003csup\\u003e43-44\\u003c/sup\\u003e.\\u003c/p\\u003e\\n\\u003cp\\u003eTo our knowledge, this is the first study to identify CAT score as a predictor of progression in early-stage FILD. The CAT score had previously been associated with survival in advanced FILD patients receiving oxygen therapy\\u003csup\\u003e21\\u003c/sup\\u003e. Our findings suggest that CAT, along with 6MWT desaturation and D\\u003csub\\u003eLCO\\u003c/sub\\u003e, can help identify patients with mild FILD who may benefit from early antifibrotic therapy. Accurate diagnosis of ILD subtype and radiological pattern by MDD can further inform treatment decisions.\\u003c/p\\u003e\\n\\u003cp\\u003eThe present study has some limitations. First, the sample size was relatively small, and larger studies are needed to validate our findings. Second, the starting date of annual progression (day 0) was defined as the date of hospitalization for the examination program for FILD, not the day of diagnosis. Nevertheless, during the period from diagnosis day to the starting date of the present study there was no apparent difference between the groups with and without annual progression. Third, while we adjusted for established confounders, other unknown factors may have influenced disease progression.\\u003c/p\\u003e\"},{\"header\":\"Conclusion\",\"content\":\"\\u003cp\\u003eIn conclusion, this study identified exercise-induced hypoxia, impaired gas change, higher CAT score, GAP stage I, definite UIP pattern on CT, and diagnosis with IPF and fibrotic HP as independent predictors of annual progression in mild FILD. These prognostic factors can help in selecting patients who may benefit from early intervention via antifibrotic therapy, potentially improving outcomes of this challenging disease.\\u003c/p\\u003e\"},{\"header\":\"Declarations\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eFinancial disclosures\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe study\\u0026rsquo;s expenses were paid from the research funds of Department of Respirology, NHO Kyushu Medical Center.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAuthors\\u0026rsquo; contributions\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eM.O. initiated the study and wrote the main manuscript and figure. K.F., T.C., and A.S. contributed to the radiological evaluations in multidisciplinary discussion diagnosis. K.T. and Y.Z. contributed to the pathological evaluations in multidisciplinary discussion diagnosis. A.K. performed the statistical analyses. Y.N. enrolled the cases. M.O. M.T., H.T., N.M., and T.N. performed the data analysis and interpretation. T.Y. and T.H. supervised the research. All authors fulfill the authorship criteria and have read and approved the final version of the manuscript.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAcknowledgments\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eWe thank Ms. Natsuko Shibata, M.T. of the Department of Respirology, NHO Kyushu Medical Center, for sorting medical data.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eConflicts of interest statements\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eMasaki Okamoto, Toyoshi Yanagihara, and Tomoaki Hoshino received more than 1,000,000 JPY as research funding from Nippon Boehringer-Ingelheim, Co., Ltd.\\u003c/p\\u003e\\n\\u003cp\\u003eKiminori Fujimoto received more than 1,000,000 JPY as research funding from Micron KK.\\u003c/p\\u003e\\n\\u003cp\\u003eMasaki Okamoto and Yoshiaki Zaizen received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, Co., Ltd.\\u003c/p\\u003e\\n\\u003cp\\u003eThe other co-authors have no potential conflicts of interest.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAvailability of data and materials\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eEthics approval and consent to participate\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eWe received specific approval for all procedures from the Institutional Review Board (IRB) of NHO Kyushu Medical Center. The approval number (date of IRB approval) of our study is 22C080 (December 21, 2022). All research was performed in accordance with relevant guidelines/regulations.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eConsent for publication\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eInformed consent was obtained in the form of opt-out methodology for the study period. Informed consent was waived by the Kyushu Medical Center\\u003c/p\\u003e\"},{\"header\":\"References\",\"content\":\"\\u003col\\u003e\\n \\u003cli\\u003eRaghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205: e18-e47.\\u003c/li\\u003e\\n \\u003cli\\u003eRaghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198: e44\\u0026ndash;e68.\\u003c/li\\u003e\\n \\u003cli\\u003eRaghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011, 183, 788\\u0026ndash;824.\\u003c/li\\u003e\\n \\u003cli\\u003eTravis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188: 733-748.\\u003c/li\\u003e\\n\\u003c/ol\\u003e\\n\\u003col\\u003e\\n \\u003cli\\u003eNatsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190: 773-779.\\u003c/li\\u003e\\n \\u003cli\\u003eKhor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ; Austin ILD Registry and CARE-PF Investigators. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions. Am J Respir Crit Care Med. 2023; 207: 102-105.\\u003c/li\\u003e\\n \\u003cli\\u003eRicheldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071\\u0026ndash;2082.\\u003c/li\\u003e\\n \\u003cli\\u003eKing TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083\\u0026ndash;2092.\\u003c/li\\u003e\\n \\u003cli\\u003ePetnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest 2021; 160: 1751-1763.\\u003c/li\\u003e\\n \\u003cli\\u003eFlaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381: 1718-1727.\\u003c/li\\u003e\\n \\u003cli\\u003eRyerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014; 145: 723-728.\\u003c/li\\u003e\\n \\u003cli\\u003eMaher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 2019; 7: 771-779.\\u003c/li\\u003e\\n \\u003cli\\u003eKolb M, Flaherty KR, Silva RS, Prasse A, Vancheri C, Mueller H, et al. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics. Adv Ther. 2023; 40: 5536-5546.\\u003c/li\\u003e\\n \\u003cli\\u003eRyerson CJ, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, et al. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Res. 2019; 5: 00127\\u0026ndash;2018.\\u003c/li\\u003e\\n \\u003cli\\u003evan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2013; 65: 2737\\u0026ndash;2747.\\u003c/li\\u003e\\n \\u003cli\\u003eBohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347.\\u003c/li\\u003e\\n \\u003cli\\u003eAletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569\\u0026ndash;2581.\\u003c/li\\u003e\\n \\u003cli\\u003eShiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren\\u0026apos;s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017; 76: 9-16.\\u003c/li\\u003e\\n \\u003cli\\u003eChung SA, Langford CA, Maz M, Abril A, Gorelik M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021; 73: 1366-1383.\\u003c/li\\u003e\\n \\u003cli\\u003eCollard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.\\u003c/li\\u003e\\n \\u003cli\\u003eKataoka K, Oda K, Takizawa H, Ogura T, Miyamoto A, Inoue Y, et al. Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy. Sci Rep. 2023; 13: 13664.\\u003c/li\\u003e\\n \\u003cli\\u003eVenkatesan P. GOLD COPD report: 2024 update. Lancet Respir Med. 2024; 12: 15-16.\\u003c/li\\u003e\\n \\u003cli\\u003eYoza Y, Ariyoshi K, Honda S, Taniguchi H, Senjyu H. Development of an activity of daily living scale for patients with COPD: the Activity of Daily Living Dyspnoea scale. Respirology. 2009; 14: 429-435.\\u003c/li\\u003e\\n \\u003cli\\u003eMahler DA, Mackowiak JI. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest. 1995; 107: 1585-1589.\\u003c/li\\u003e\\n \\u003cli\\u003eMatsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, et al. Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Intern Med. 2017; 56: 1637-1644.\\u003c/li\\u003e\\n \\u003cli\\u003eMiller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319\\u0026ndash;338.\\u003c/li\\u003e\\n \\u003cli\\u003eATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Guideline Am J Respir Crit Care Med. 2002; 166: 111-117.\\u003c/li\\u003e\\n \\u003cli\\u003eGoddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol. 1982; 33: 379-387.\\u003c/li\\u003e\\n \\u003cli\\u003eNoda Y. et al. Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer. Sci Rep 2022; 12: 8881.\\u003c/li\\u003e\\n \\u003cli\\u003eWong AW, Liang J, Cottin V, Ryerson CJ. Diagnostic Features in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review. Ann Am Thorac Soc. 2020; 17: 1333-1336..\\u003c/li\\u003e\\n \\u003cli\\u003eKondoh Y, Taniguchi H, Kataoka K, Furukawa T, Ando M, Murotani K, et al. Disease severity staging system for idiopathic pulmonary fibrosis in Japan. Respirology. 2017; 22: 1609-1614.\\u003c/li\\u003e\\n \\u003cli\\u003eSugino K, Ono H, Watanabe N, Ando M, Tsuboi E, Homma S, et al. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC Pulm Med. 2021; 21: 218.\\u003c/li\\u003e\\n \\u003cli\\u003eLama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168: 1084-1090.\\u003c/li\\u003e\\n \\u003cli\\u003eNishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 36: 1067-1072.\\u003c/li\\u003e\\n \\u003cli\\u003eLederer DJ, Arcasoy SM, Wilt JS, D\\u0026apos;Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174: 659-664.\\u003c/li\\u003e\\n \\u003cli\\u003edu Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 183: 1231-1237.\\u003c/li\\u003e\\n \\u003cli\\u003eEgan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005; 60: 270-273.\\u003c/li\\u003e\\n \\u003cli\\u003eAdegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Chung JH, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019; 16: 580\\u0026ndash;588.\\u003c/li\\u003e\\n \\u003cli\\u003eRaghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 202: e36-e69.\\u003c/li\\u003e\\n \\u003cli\\u003eFern\\u0026aacute;ndez P\\u0026eacute;rez ER, Travis WD, Lynch DA, Brown KK, Johannson KA, Selman M, et al. Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report. Chest. 2021; 160: e97-e156.\\u003c/li\\u003e\\n \\u003cli\\u003eAlberti ML, Malet Ruiz JM, Fern\\u0026aacute;ndez ME, Fassola L, Caro F, Rold\\u0026aacute;n IB, Paulin F. Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology. 2020; 26: 3-9.\\u003c/li\\u003e\\n \\u003cli\\u003eGimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018; 73: 391-392.\\u003c/li\\u003e\\n \\u003cli\\u003eFern\\u0026aacute;ndez P\\u0026eacute;rez ER, Swigris JJ, Forss\\u0026eacute;n AV, Solomon JJ, Huie TJ, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144: 1644\\u0026ndash;1651.\\u003c/li\\u003e\\n \\u003cli\\u003eSalisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest. 2019; 155: 699-711.\\u003c/li\\u003e\\n\\u003c/ol\\u003e\"},{\"header\":\"Tables\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eTable 1A. Patients\\u0026rsquo; characteristics\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"662\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"42.835595776772244%\\\" colspan=\\\"2\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAnnual progression of FILD\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e \\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAll cases\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eYes\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNo\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eP\\u003c/em\\u003e\\u003c/strong\\u003e\\u003cstrong\\u003e\\u0026nbsp;value\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eNumber\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e84\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e31 (37%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e53 (63%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.65\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eAge (years)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e69.5 (64.4-75.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e72.1 (68.8-76.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e67.4 (61.0-74.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.0096*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eMale gender\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e45 (54%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e18 (58%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e27 (51%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.65\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eSmoker\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e33 (39%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e12 (39%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e21 (40%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eBody mass index (kg/m\\u003csup\\u003e2\\u003c/sup\\u003e)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e23.4 (20.6-25.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e23.3 (20.7-25.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e23.4 (20.5-25.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.89\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eFILD subtype\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e IPF\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e21 (25%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e11 (36%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e10 (19%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e NSIP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e1 (1%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e2 (4%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e SR-ILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e3 (4%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e3 (6%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e Fibrotic HP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e18 (21%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e12 (39%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e6 (11%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.0052*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e CTD-ILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e34 (40%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e6 (19%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e27 (51%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.0054*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e UC-ILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e7 (8%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e1 (3%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e6 (11%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.25\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eHRCT pattern\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e Definite UIP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e14 (17%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e9 (29%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e5 (9 %)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.0098*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e Probable UIP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e10 (12%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e10 (19%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e Indeterminate for UIP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e15 (18%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e6 (19%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e9 (17%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e Alternative diagnosis\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e45 (54%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e16 (52%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e29 (55%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eCT-Goddard score (0-24)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e8.0 (6.0-11.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e8.0 (6.0-11.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e8.0 (6.0-11.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.69\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003emMRC scale (0/1/2/3/4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e18 / 43 / 16 / 5 / 2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e7 / 14 / 6 / 3 / 1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e11 /29 / 10 / 2 / 1\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.75\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eGAP stage 0 / 1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e45 (54%) / 39 (46%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e12 (39%) / 19 (61%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e33 (62%) / 20 (38%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.044*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePulmonary function\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e FVC (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e84.7 (69.4-96.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e79.8 (65.5-92.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e88.3 (71.1-99.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e D\\u003csub\\u003eLCO\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e66.2 (57.9-82.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e68.6 (56.7-83.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e65.4 (58.9-81.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.84\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSix-months walk test\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e91.5 (88.0-94.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e89.0 (85.0-92.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e92.0 (89.0-95.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.0034*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Less than 90%\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e31 (37%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e17 (55%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e14 (26%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.011*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Decrease in SpO\\u003csub\\u003e2\\u0026nbsp;\\u003c/sub\\u003e(%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e5.0 (3.0-8.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e7.0 (4.0-10.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e4.0 (1.9-6.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.0011*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; More than 4%\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e55 (65%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e24 (77%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e31 (58%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.098\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Highest mBorg scale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e3 (1-4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e4.0 (1.3-5.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e2.0 (1.0-4.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.057\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Walk distance (m)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e390.0 (340.0-487.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e375.0 (300.0-460.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e415.0 (342.5-502.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.083\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSerum biomarker\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eCRP (mg/dL)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e0.11 (0.060-0.32)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e0.11 (0.050-0.30)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e0.11 (0.060-0.32)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.77\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eKL-6 (IU/mL)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e880.5 (535.8-1391.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e876.0 (549.0-1747.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e929.0 (493.5-1303.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.78\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003eMonocyte counts (/\\u0026micro;L)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e383.7 (282.6-470.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e372.4 (279.0-484.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e387.6 (303.1-466.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.61\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"24.283559577677224%\\\"\\u003e\\n \\u003cp\\u003ePeriod from FILD\\u0026nbsp;\\u003c/p\\u003e\\n \\u003cp\\u003ediagnosis to admission\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e57.5 (26.3-609.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e54.0 (26.0-610.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.417797888386122%\\\"\\u003e\\n \\u003cp\\u003e71.0 (26.0-629.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"11.463046757164404%\\\"\\u003e\\n \\u003cp\\u003e0.92\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eData are expressed as the median (25th to 75th percentiles of the interquartile range [IQR]), unless otherwise stated. FILD, fibrotic interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; SR-ILD, smoking-related interstitial lung disease; HP, hypersensitivity pneumonia; CTD, connective tissue disease; UC-ILD, unclassifiable interstitial lung disease; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia; mMRC, modified medical research council; GAP, gender-age-physiology; FVC, forced vital capacity; D\\u003csub\\u003eLCO\\u003c/sub\\u003e, diffusing capacity of the lung for carbon monoxide; SpO\\u003csub\\u003e2\\u003c/sub\\u003e, saturation of percutaneous oxygen; mBorg, modified Borg; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6;\\u0026nbsp;*\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 1B. Patients\\u0026rsquo; reported outcomes and muscle strength\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"614\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"40%\\\" colspan=\\\"2\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAnnual progression of FILD\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e \\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAll cases\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eYes\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNo\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eP\\u003c/em\\u003e\\u003c/strong\\u003e\\u003cstrong\\u003e\\u0026nbsp;value\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNumber\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e84\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e31 (37%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e53 (63%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePatient reported outcome\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;CAT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e13 (7-19)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e16.0 (9.0-25.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e10.5 (7.0-17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.068\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;NRADL\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e93.0 (81.0-98.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e90.0 (74.8-97.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e94.0 (85.0-98.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.13\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;SF-36\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Physical function\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e75.0 (50.0-90.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e65.0 (50.0-85.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e80.0 (51.3-93.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.19\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Role physical\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e75.0 (55.5-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e62.5 (43.8-87.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e87.5 (56.3-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.048*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Body pain\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e66.0 (41.0-84.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e52.0 (36.5-74.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e72.0 (42.0-84.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.14\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; General health\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e50.0 (37.5-57.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e45.0 (35.0-57.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e50.0 (40.0-58.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.32\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Vitality\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e56.3 (43.8-68.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e50.0 (37.5-67.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e62.3 (45.4-68.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Social function\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e87.5 (55.0-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e75.0 (50.0-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e87.5 (62.5-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.14\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Role emotional\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e83.3 (50.0-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e66.7 (50.0-91.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e95.9 (60.4-100.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.032*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Mental health\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e70.0 (55.0-80.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e60.0 (55.0-72.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e70.0 (55.0-80.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.26\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;HADS\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003eAnxiety\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e5.0 (2.0-7.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e5.0 (3.0-7.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e4.0 (2.0-7.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.13\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003eDepression\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e6.0 (4.0-8.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e6.0 (4.0-9.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e6.0 (4.0-8.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.75\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eMuscle strength\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003eLimb skeletal muscle mass\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e17.8 (14.8-21.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e18.0 (14.7-21.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e17.8 (15.0-22.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.65\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003eKnee extension strength\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e22.3 (16.7-33.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e25.1 (18.0-32.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e23.9 (19.6-30.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.99\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"29.26829268292683%\\\"\\u003e\\n \\u003cp\\u003eGrip strength\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e23.7 (18.2-31.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e19.5 (15.5-32.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20%\\\"\\u003e\\n \\u003cp\\u003e23.6 (19.0-33.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.731707317073171%\\\"\\u003e\\n \\u003cp\\u003e0.13\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eData are expressed as the median (25th to 75th percentiles of the interquartile range [IQR]), unless otherwise stated. FILD, fibrotic interstitial lung disease; CAT, chronic obstructive pulmonary disease assessment test; NRADL, the Nagasaki University Respiratory Activities of Daily Living Questionnaire; SF-36, Short Form 36; HADS, Hospital Anxiety and Depression Scale. *\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 2. Patients\\u0026rsquo; outcome\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"699\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"39.19885550786838%\\\" colspan=\\\"2\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAnnual progression of FILD\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e \\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAll cases\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eYes\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNo\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eP\\u003c/em\\u003e\\u003c/strong\\u003e\\u003cstrong\\u003e\\u0026nbsp;value\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNumber\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e84\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e31 (37%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e53 (63%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"50%\\\" colspan=\\\"2\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eComponent of annual progression of FILD\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003eMore than 10% decrease in FVC\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e13 (16%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e13 (42%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003eMore than 15% decrease in D\\u003csub\\u003eLCO\\u003c/sub\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e21 (27%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e21 (68%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003eDeveloping acute exacerbation\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e1 (1%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e1 (3%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003eMortality due to FILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eExposure of drug therapy\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Antifibrotic drug\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e24 (29%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e11 (36%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e13 (25%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e0.32\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Nintedanib\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e33 (39%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e10 (32%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e13 (25%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e0.46\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Pirfenidone\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e1 (1%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e1 (3%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e0.37\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Immunosuppressive therapy\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e40 (48%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e11 (36%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e29 (55%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e0.11\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Corticosteroid\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e36 (43%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e11 (36%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e25 (47%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e0.36\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"31.044349070100143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Immunosuppressant\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e20 (24%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.314735336194563%\\\"\\u003e\\n \\u003cp\\u003e4 (13%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"18.88412017167382%\\\"\\u003e\\n \\u003cp\\u003e16 (30%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"10.872675250357654%\\\"\\u003e\\n \\u003cp\\u003e0.11\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eData are expressed as the median (25th to 75th percentiles of the interquartile range [IQR]), unless otherwise stated. FILD, fibrotic interstitial lung disease; FVC, forced vital capacity; D\\u003csub\\u003eLCO\\u003c/sub\\u003e, diffusing capacity of the lung for carbon monoxide. *\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 3. Univariate analysis of factors associated with disease progression using the logistic regression analysis\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003col start=\\\"1\\\" style=\\\"list-style-type: upper-alpha;\\\"\\u003e\\n \\u003cli\\u003e\\u003cstrong\\u003ePart 1\\u003c/strong\\u003e\\u003c/li\\u003e\\n\\u003c/ol\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"491\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e \\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eOR\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e95%CI\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSE\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eP\\u003c/em\\u003e\\u003c/strong\\u003e\\u003cstrong\\u003e\\u0026nbsp;value\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eAge (years)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e56.4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e3.3-1583.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.0286\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.0041*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eMale gender\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e1.3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.55-3.3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.228\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eSmoker\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e1.0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.42-2.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.232\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.93\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eBody mass index(kg/m\\u003csup\\u003e2\\u003c/sup\\u003e)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.73\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.078-6.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.0580\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.78\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eILD subtype\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;IPF\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e2.4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.86-6.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.257\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.094\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Fibrotic HP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e4.9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e1.7-16.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.285\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.036*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;CTD-ILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.23\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.075-0.62\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.266\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.0033*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;UC-ILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.26\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.013-1.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.547\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.17\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eDefinite pattern on CT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e3.9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e1.2-14.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.307\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.022*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eCT-Goddard score (0-24)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e1.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.20-11.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.0853\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.69\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003emMRC grade (0/1/2/3/4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e2.0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.28-14.3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.2470\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.48\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003eGAP stage I\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e2.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e1.1-6.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.234\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.036*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePulmonary function\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;FVC (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e0.26\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.033-1.8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.0124\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.18\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;D\\u003csub\\u003eLCO\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e1.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.14-16.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.0126\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e0.74\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSix-months walk test\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e0.069\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.0065-0.57\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.0513\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.013*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Highest mBorg scale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e5.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.89-39.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.1060\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.066\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e20.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e2.8-183.9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.0480\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.0023*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Walk distance (m)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e0.087\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.0064-0.97\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.00210\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.047*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSerum biomarker\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;CRP (mg/dL)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e0.13\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.0011-2.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.518\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.18\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;KL-6 (IU/mL)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e1.9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e0.29-12.7\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.000194\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.48\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.552845528455286%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Monocyte counts (/\\u0026micro;L)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.414634146341463%\\\"\\u003e\\n \\u003cp\\u003e0.041\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.308943089430894%\\\"\\u003e\\n \\u003cp\\u003e4.073e-5-5.0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.276422764227643%\\\"\\u003e\\n \\u003cp\\u003e0.116\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.447154471544716%\\\"\\u003e\\n \\u003cp\\u003e0.23\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eOR, odds ratio; SE, standard error; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; HP, hypersensitivity pneumonia; CTD, connective tissue disease; UC-ILD, unclassifiable interstitial lung disease; UIP, usual interstitial pneumonia; mMRC, modified Medical Research Council; GAP, gender-age-physiology; FVC, forced vital capacity; D\\u003csub\\u003eLCO\\u003c/sub\\u003e, diffusing capacity of the lung for carbon monoxide; mBorg, modified Borg; SpO\\u003csub\\u003e2\\u003c/sub\\u003e, saturation of percutaneous oxygen; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6. *\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant.\\u003cbr\\u003e\\u003cstrong\\u003eB\\u003c/strong\\u003e. \\u003cstrong\\u003ePart 2\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"473\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e \\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eOR\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e95%CI\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSE\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eP\\u003c/em\\u003e\\u003c/strong\\u003e\\u003cstrong\\u003e\\u0026nbsp;value\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePatient reported outcome\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;CAT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e6.9\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.98-55.4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0261\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.052\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;NRADL\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.25\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.023-2.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0156\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.24\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;SF-36\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Physical function\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.38\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.061-2.3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.00911\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.28\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Role physical\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.25\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.048-1.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.00814\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.086\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Body pain\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.30\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.053-1.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.00867\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; General health\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.16\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.011-2.0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0144\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Vitality\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.28\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.033-2.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0113\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.23\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Social function\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.29\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.050-1.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.00866\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Role emotional\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.36\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.075-1.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.00775\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.18\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Mental health\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.19\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.015-2.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0126\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.18\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;HADS-A\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e8.0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.60-131.8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0797\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;HADS-D\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e3.0\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.25-37.2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0738\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.39\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eMuscle strength\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Limb skeletal muscle mass\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.51\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.053-4.3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0539\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.54\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Knee extension strength\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.14\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.0087-1.6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0224\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Grip strength\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e1.1\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.11-10.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.0254\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.94\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"72.03389830508475%\\\" colspan=\\\"3\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDrug exposure more than 180 days\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Antifibrotic drug\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e1.7\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.64-4.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.246\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.29\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.04237288135593%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;Immunosuppressive therapy\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.076271186440678%\\\"\\u003e\\n \\u003cp\\u003e0.34\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"19.915254237288135%\\\"\\u003e\\n \\u003cp\\u003e0.090-1.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.3070\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.983050847457626%\\\"\\u003e\\n \\u003cp\\u003e0.063\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eOR, odds ratio; SE, standard error; CAT, chronic obstructive pulmonary disease assessment test; NRADL, the Nagasaki University Respiratory Activities of Daily Living Questionnaire; SF-36, Short Form 36; HADS-A, Hospital Anxiety and Depression Scale\\u0026ndash;Anxiety; HADS-D, Hospital Anxiety and Depression Scale\\u0026ndash;Depression. *\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 4. Multivariate analysis of factors associated with overall survival using the logistic regression analyses\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"983\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e \\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eModel 1\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eModel 2\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eModel 3\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eModel 4\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eModel 5\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eModel 6\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eAge (years)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eGender Male\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\" valign=\\\"bottom\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eIPF\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e12.2 (2.9-62.7)\\u003cbr\\u003e\\u0026nbsp;P=0.0019*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eFibrotic HP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e17.1 (3.7-107.8)\\u003cbr\\u003e\\u0026nbsp;P=0.00010*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e17.1 (3.7-107.8)\\u003cbr\\u003e\\u0026nbsp;P=0.00010*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e18.8 (4.2-115.1)\\u003cbr\\u003e\\u0026nbsp;P\\u0026lt;0.00010*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e17.1 (3.7-107.8)\\u003cbr\\u003e\\u0026nbsp;P=0.00010*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e8.5 (2.2-39.7)\\u003cbr\\u003e\\u0026nbsp;P=0.00040*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e9.6 (2.5-43.8)\\u003cbr\\u003e\\u0026nbsp;P=0.00080*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eCTD-ILD\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eCT-definite UIP pattern\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e7.2 (1.4-44.7)\\u003cbr\\u003e\\u0026nbsp;P=0.020*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e7.2 (1.4-44.7)\\u003cbr\\u003e\\u0026nbsp;P=0.020*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e7.5 (1.5-44.0)\\u003cbr\\u003e\\u0026nbsp;P=0.013*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e7.2 (1.4-44.7)\\u003cbr\\u003e\\u0026nbsp;P=0.020*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e12.0 (2.6-69.5)\\u003cbr\\u003e\\u0026nbsp;P=0.0014*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eCT-Goddard score (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eFVC (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eD\\u003csub\\u003eLCO\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e607.3 (8.8-112270.1)\\u003cbr\\u003e\\u0026nbsp;P=0.0022*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e607.3 (8.8-112270.1)\\u003cbr\\u003e\\u0026nbsp;P=0.0022*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e173.3 (3.8-17780.6)\\u003cbr\\u003e\\u0026nbsp;P=0.0072*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e607.3 (8.8-112270.1)\\u003cbr\\u003e\\u0026nbsp;P=0.0022*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e362.0 (7.3-42343.1)\\u003cbr\\u003e\\u0026nbsp;P=0.0025*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e237.1 (5.1-24728.6)\\u003cbr\\u003e\\u0026nbsp;P=0.0044*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eGAP stage I\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e4.9 (1.2-25.9)\\u003cbr\\u003e\\u0026nbsp;P=0.029*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e4.9 (1.2-25.9)\\u003cbr\\u003e\\u0026nbsp;P=0.029*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e4.8 (1.2-24.4)\\u003cbr\\u003e\\u0026nbsp;P=0.026*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e4.9 (1.2-25.9)\\u003cbr\\u003e\\u0026nbsp;P=0.029*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003e6MWT-lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e0.016 (0.00034-0.41)\\u003cbr\\u003e\\u0026nbsp;P=0.0012*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003e6MWT-decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e140.8 (5.5-6424.7)\\u003cbr\\u003e\\u0026nbsp;P=0.0021*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e140.8 (5.5-6424.7)\\u003cbr\\u003e\\u0026nbsp;P=0.0021*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e140.8 (5.5-6424.7)\\u003cbr\\u003e\\u0026nbsp;P=0.0021*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e123.1 (6.0-4403.2)\\u003cbr\\u003e\\u0026nbsp;P=0.0013*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e111.1 (5.5-3519.7)\\u003cbr\\u003e\\u0026nbsp;P=0.0037*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003e6MWT-highest mBorg scale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003e6MWD (m)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eCAT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e36.0 (2.0-1021.1)\\u003cbr\\u003e\\u0026nbsp;P=0.014*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e36.0 (2.0-1021.1)\\u003cbr\\u003e\\u0026nbsp;P=0.014*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e23.0 (1.5-492.9)\\u003cbr\\u003e\\u0026nbsp;P=0.024*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003e36.0 (2.0-1021.1)\\u003cbr\\u003e\\u0026nbsp;P=0.014*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e76.5 (4.4-2161.5)\\u003cbr\\u003e\\u0026nbsp;P=0.0024*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003e54.3 (3.2-1425.2)\\u003cbr\\u003e\\u0026nbsp;P=0.0048*\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eSF-36 Role Physical\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eAntifibrotic drug use\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"18.329938900203665%\\\"\\u003e\\n \\u003cp\\u003eImmunosuppressive therapy\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.460285132382893%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.441955193482688%\\\"\\u003e\\n \\u003cp\\u003eN.S.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eUpper row, odds ratio (95% confidence interval); lower row, \\u003cem\\u003eP\\u003c/em\\u003e value; SE, standard error; IPF, idiopathic pulmonary fibrosis; HP, hypersensitivity pneumonia; CTD, connective tissue disease; UC-ILD, unclassifiable interstitial lung disease; CT, computed tomography; UIP, usual interstitial pneumonia; FVC, forced vital capacity; D\\u003csub\\u003eLCO\\u003c/sub\\u003e, diffusing capacity of the lung for carbon monoxide; GAP, gender-age-physiology; 6MWT, 6-minute walk test; SpO\\u003csub\\u003e2\\u003c/sub\\u003e, saturation of percutaneous oxygen; mBorg, modified Borg; CAT, chronic obstructive pulmonary disease assessment test; SF-36, Short Form 36. *\\u003cem\\u003eP\\u003c/em\\u003e\\u0026lt;0.05 is regarded as statistically significant\\u003c/p\\u003e\"}],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":true,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":false,\"hideJournal\":true,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":false,\"isAuthorSuppliedPdf\":false,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":false,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true},\"keywords\":\"fibrosing interstitial lung disease, 6-minute walk test, progression, gender-age-physiology stage, prognostic factor\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-4513072/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-4513072/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"\\u003cp\\u003eThe prognostic factors in mild fibrosing interstitial lung disease (FILD) have not been established. We retrospectively attempted to identify predictive factors of annual progression in mild FILD with gender-age-physiology (GAP) stage 0 or I using logistic regression analysis, adjusting for confounding factors associated with prognosis. Annual progression was defined as more than 10% decrease in forced vital capacity (FVC) or 15% decrease in diffusing capacity of the lungs for carbon monoxide (D\\u003csub\\u003eLCO\\u003c/sub\\u003e), developing acute exacerbation, or death due to FILD. Univariate analysis showed that higher age, diagnosis of fibrotic hypersensitivity pneumonia (HP), definite usual interstitial pneumonia (UIP) pattern on CT, GAP stage I, lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e, and shorter walk distance in 6-minute walk test (6MWT) were significantly associated with a higher incidence of annual progression. Multivariate analysis showed that independent predictive factors of higher annual progression were diagnosis of idiopathic pulmonary fibrosis and fibrotic HP, definite UIP pattern on CT, GAP stage I, lower D\\u003csub\\u003eLCO\\u003c/sub\\u003e, lowest SpO\\u003csub\\u003e2\\u003c/sub\\u003e and decrease in SpO\\u003csub\\u003e2\\u003c/sub\\u003e in the 6MWT, and higher chronic pulmonary emphysema assessment test. Evaluating prognostic factors in patients with mild FILD has potential to identify patients who are suitable for early intervention with antifibrotic therapy.\\u003c/p\\u003e\",\"manuscriptTitle\":\"Predictive factors of progression in fibrosing interstitial lung disease patients with gender-age-physiology stage 0 or I\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2024-06-26 18:56:33\",\"doi\":\"10.21203/rs.3.rs-4513072/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true}}],\"origin\":\"\",\"ownerIdentity\":\"5172f991-ae7a-4ae1-87c6-f56f63f2740d\",\"owner\":[],\"postedDate\":\"June 26th, 2024\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"posted\",\"subjectAreas\":[{\"id\":33369889,\"name\":\"Biological sciences/Physiology\"},{\"id\":33369890,\"name\":\"Biological sciences/Physiology/Respiration\"}],\"tags\":[],\"updatedAt\":\"2024-07-08T05:51:06+00:00\",\"versionOfRecord\":[],\"versionCreatedAt\":\"2024-06-26 18:56:33\",\"video\":\"\",\"vorDoi\":\"\",\"vorDoiUrl\":\"\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-4513072\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-4513072\",\"identity\":\"rs-4513072\",\"version\":[\"v1\"]},\"buildId\":\"qtupq5eGEP_6zYnWcrvyt\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}